XKRX
096530
Market cap1.30bUSD
Oct 08, Last price
38,150.00KRW
1D
-1.93%
1Q
31.55%
Jan 2017
9.16%
IPO
-1.84%
Name
Seegene Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Key people
Jong Yun Cheon
Co-Chief Executive Officer, Director · since 2024
Beom Jun Kim
Vice President · since 2023
Jun Beom Kim
Vice President · since 2024
Gi Seon Lee
Vice President · since 2020
Sang Heon Shin
Vice President · since 2022
Dae Ho Shin
Vice President · since 2023
Bu Hyeon Yang
Vice President · since 2021
Dae Hyeok Ahn
Managing Director · since 2022
Eun Sin Bae
Managing Director · since 2024
Eun Cheol Cho
Managing Director · since 2021
Dae Yeop Choi
Managing Director · since 2018
Yin Taek Hwang
Managing Director · since 2021
Seung Gu Kang
Managing Director · since 2020
Do Yeon Kim
Managing Director · since 2020
Jin Ho Kim
Managing Director · since 2017
Jeong Yong Kim
Managing Director · since 2023
Seong Yeol Kim
Managing Director · since 2021
Yong Rae Lee
Managing Director · since 2021
Si Won Noh
Managing Director · since 2023
Dong Ju Seo
Managing Director · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||